The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer

European Urology

Volumn 60, Issue 3, 2011, Pages 448-454

  Powles, Thomas ^a   Blank, Christian ^b   Chowdhury, Simon ^c   Horenblas, Simon ^b   Peters, John ^d   Shamash, Jonathan ^a   Sarwar, Naveed ^a   Boleti, Ekaterini ^e   Sahdev, Anju ^a   O'Brien, Tim ^c   Berney, Dan ^a   Beltran, Luis ^d   Nathan, Paul ^f   Haanen, John ^b   Bex, Axel ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

FDG PET; Metastatic renal cancer; Nephrectomy; Sunitinib

Indexed keywords

SUNITINIB;

ARTICLE; BLEEDING; CANCER GRADING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CANCER; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NECROSIS; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; WOUND HEALING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEPHRECTOMY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRROLES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960977418     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.028     Document Type: Article

References (20)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
2. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-63.
3. Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 2010;58:819-28.
4. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9. (Pubitemid 33126820)
5. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70. (Pubitemid 32913522)
6. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:60-6.
7. Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011;22:1041-7.
8. Chapin B, Delacroix E, Culp G, Gonzalez C, Wood C. Postoperative complications from cytoreductive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2011;29(Suppl 7), abstract 300.
9. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010;28:1502-7.
10. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076-81.
11. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184:859-64.
12. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009;115(Suppl 10):2355-60.
13. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40. (Pubitemid 29368255)
14. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
15. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
16. Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81. (Pubitemid 46849157)
17. Motzer RJ, Escudier B, Oudard S, et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
18. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009;9:82.
19. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010;9:15-9.
20. Van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102:803-9.